“An effectiveness result of 50% achieved during the peak COVID-19 delta variant wave in India, in a high risk study population of physicians and healthcare workers, in a hospital environment, and who are challenged repeatedly with high viral loads, provides insights into the efficacy and effectiveness of Covaxin,” the firm mentioned in an announcement
“These results compare well with the 65.2% efficacy against the delta variant obtained during the controlled phase III clinical trials of Covaxin conducted among the general population. This study also shows that Covaxin meets the WHO efficacy criteria for COVID-19 vaccines for the dreaded Delta variants,” the assertion added.
The research, titled “Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study” assessed 2,714 hospital staff at AIIMS in Delhi, from April 15–May 15, who have been symptomatic and underwent RT-PCR check for COVID-19 detection. The outcomes have been revealed in The Lancet Infectious Diseases Journal.
Results of an interim research carried out by AIIMS has proven that two doses of Covaxin, the indigenous vaccine developed by Indian Council of Medical Research (ICMR) in collaboration with Bharat Biotech, is 50% efficient in stopping symptomatic an infection due to COVID-19. This is decrease than the 77.8 % efficacy claimed by Bharat Biotech after part 3 trials of the vaccine.
Covaxin, also referred to as BBV152, a two-dose routine, with a niche of 28 days between every dose developed in collaboration with the Indian Council of Medical Research (ICMR) one of the two most widely-used vaccines in the nationwide inoculation train. On November 3, it was granted Emergency Use Listing (EUL) by the World Health Organization (WHO).